Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 58

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 58
---
 in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms.

Foreign Exchange Risks

Our financial statements are denominated in U.S. dollars and financial results are denominated in U.S. dollars, while a significant portion of our business is conducted, and a substantial portion of our operating expenses are payable, in currencies other than the U.S. dollar.

Exchange rate fluctuations may have an adverse impact on our future revenues, if any, or expenses as presented in the financial statements. We may in the future use financial instruments, such as forward foreign currency contracts, in its management of foreign currency exposure. These contracts would primarily require us to purchase and sell certain foreign currencies with or for U.S. dollars at contracted rates. We may be exposed to a credit loss in the event of non-performance by the counterparties of these contracts. In addition, these financial instruments may not adequately manage our foreign currency exposure. Our results of operations could be adversely affected if we are unable to successfully manage currency fluctuations in the future.

Effects of Inflation

Inflation generally affects Revium by increasing its research and development expenses. Revium does not believe that inflation and changing prices had a significant impact on its results of operations for any periods presented herein, but may have a significant, adverse impact in 2024.

<div align='center'>36

DESCRIPTION OF BUSINESS</div>

Business Overview

We are a pre-clinical stage biopharmaceuticalcompany that is principally engaged in the development of innovative technologies and drug-delivery technological platforms for unmet medical needs that can be implemented across a number of healthcare related fields.

Upon the closing of the Share Exchange, the Company is focusing on the development of a novel technology related to Nano-Liposomal Particles (NLP) initiated by world renowned authority in nanoparticles-based delivery systems Prof. Yehezkel Barenholz at the Hebrew University of Jerusalem.

Organization & Subsidiaries

As of the date of this Prospectus, we have two operating subsidiaries: 1) Revium Recovery, Ltd., which was established as a wholly-owned subsidiary in 2020 and 2) LipoVation Ltd., which became our wholly-owned subsidiary as July 23, 2024, upon the closing of the Share Exchange. Each wholly-owned subsidiary is organized under the laws of the State of Israel. LipoVation has several exclusive licenses and rights to develop and market a novel technology related to Nano-Liposomal Particles (NLP) initiated by Prof.